Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Racura Oncology Ltd (RAC.AX)

Racura Oncology Ltd (RAC.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Racura Oncology Ltd 1 Macquarie Place Level 36 Sydney NSW 2000 AUS

https://www.racuraoncology.com P: +61 280513043

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.

Key Statistics

Overview:

Market Capitalization, $K 421,600
Shares Outstanding, K 181,701
% of Institutional Shareholders 0.01%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -4,787 K

Growth:

1-Year Return 128.00%
3-Year Return 15.69%
5-Year Return -39.95%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.03
Dividend Payout Ratio 0.00%

RAC.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -42.40%
Return-on-Assets % -40.43%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 17.89
Book Value/Share 0.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar